ATAC21 

ATAC21, a linker-immune-stimulatory compound that can be formed by conjugating a noncleavable maleimide-PEG4 linker containing a succinimide group with an immune- stimulatory compound. ATAC21 can be combined with SBT-040 (anti-CD40 antibody) to form a conjugate^[1].

A recombinant bispecific antibody, comprises: a) a target antigen binding domain, wherein the target antigen binding domain specifically binds to a tumor associated antigen; b) an effector antigen binding domain, wherein the effector antigen binding domain specifically binds to an antigen on an antigen presenting cell and wherein the antigen is a molecule on the antigen presenting cell; c) an Fc comprising domain; and d) an immune- stimulatory compound attached to the recombinant bispecific antibody by a linker; wherein the recombinant bispecific antibody induces greater immune cell activation when the recombinant bispecific antibody is bound to the tumor associated antigen and to the antigen on the antigen presenting cell as compared to when the recombinant bispecific antibody is bound to the antigen on the antigen presenting cell but not to the tumor associated antigen^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

1072.82

C₃₈H₅₀N₁₂O₂₁P₂

2101204-23-1

O[C@H]1[C@@H](O[C@@]2([H])[C@@]1([H])OP(O)(OC[C@]3([H])[C@@]([C@H]([C@H](N4C5=C(C(N=C(N5)N)=O)N=C4)O3)O)([H])OP(O)(OC2)=O)=O)N6C7=NC=NC(NC(CCOCCOCCOCCOCCNC(CCN8C(C=CC8=O)=O)=O)=O)=C7N=C6

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Peter Armstrong Thompson, et al. Tumor targeting conjugates and methods of use thereof. WO2018140831A2.